Acute Investment Advisory’s Lam Research LRCX Stock Holding History

Acute Investment Advisory’s Portfolio LRCX Stock Details LRCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$217K	Buy	+500	New	+$152K	2.29%	18

Other funds holding LRCX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Acute Investment Advisory's LRCX Position: Q2 2026 in Review

Acute Investment Advisory opened a new position in Lam Research (LRCX) in Q2 2026: 500 shares worth $217K. The stake represents 2.29% of the portfolio and ranks #18 among its holdings.

1,967 funds tracked by Wall St. Rank hold LRCX as of Q2 2026.

Acute Investment Advisory held 500 shares of Lam Research worth $217K as of Q2 2026.
Lam Research was a new Acute Investment Advisory position in Q2 2026.
Lam Research made up 2.29% of Acute Investment Advisory's portfolio in Q2 2026, its #18 holding.
1,967 funds tracked by Wall St. Rank held Lam Research as of Q2 2026.

Based on Acute Investment Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.